https://CanadianDiabetesAndEndocrinologyToday.com/issue/feedCanadian Diabetes & Endocrinology Today2025-12-16T17:12:46+00:00Open Journal Systemshttps://CanadianDiabetesAndEndocrinologyToday.com/article/view/3-s01-JainAddressing Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) in Endocrinology Settings in Canada: From Prevalence to Patient-Centered Management2025-12-16T17:12:46+00:00Akshay Jain<p class="p1"><span class="s1">Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in Canadian endocrinology, affecting up to 70% of those with type 2 diabetes and 75% with obesity. Despite this, routine screening is rare, leading to missed detection and intervention. Advanced fibrosis, observed in 15% of cases, increases the risk of liver and cardiovascular complications. This article addresses the burden of MASLD and the need for systemic screening and patient-centred care to improve outcomes and reduce Canada’s disease burden.</span></p>2025-12-16T00:00:00+00:00Copyright (c) 2025 Canadian Diabetes & Endocrinology Today